What pharmacologic treatments are available for an adult with cannabis use disorder?

Pharmacologic Treatment for Cannabis Use Disorder

Currently, there are no FDA-approved pharmacotherapies for cannabis use disorder, and the primary treatment approach should be evidence-based psychosocial interventions, particularly cognitive behavioral therapy (CBT), with experimental medications considered only in research settings or refractory cases. 1, 2

Current Evidence for Pharmacologic Agents

Medications with Limited Experimental Evidence

THC Preparations (Dronabinol, Nabilone)

• Do not improve abstinence rates compared to placebo (RR 0.98,95% CI 0.64-1.52) 2
• May reduce withdrawal symptoms qualitatively, but evidence is weak 3
• Should be considered experimental only 2
• Well-tolerated with no increased adverse effects compared to placebo 2

Cannabidiol (CBD)

• Preliminary evidence suggests potential to reduce cannabis use in small studies 4, 5
• No significant improvement in abstinence (RR 2.23,95% CI 0.54-9.32; very low-certainty evidence) 2
• Risk of hepatotoxicity at doses ≥300 mg/day; monitor liver enzymes if used 6
• Requires larger trials before clinical recommendation 4

N-Acetylcysteine

• No improvement in abstinence (RR 1.17,95% CI 0.73-1.88) 2
• Well-tolerated with no increased adverse effects 2
• May warrant further investigation but insufficient evidence for routine use 3

Nabiximols (THC/CBD Combination)

• Shows broader efficacy in reducing cannabis use and improving abstinence compared to pure THC agonists 5
• Not FDA-approved in the United States 1
• Represents endocannabinoid modulation approach that appears more promising than pure agonists 5

Medications with Insufficient or Negative Evidence

Antidepressants (SSRIs, Mixed-Action)

• No difference in abstinence or treatment outcomes 2, 3
• Probably of little value for cannabis use disorder 3

Anticonvulsants and Mood Stabilizers

• May reduce treatment completion (RR 0.66,95% CI 0.47-0.92) 2
• Higher withdrawal from treatment due to adverse effects (RR 2.88,95% CI 1.05-7.86) 2
• Limited therapeutic value given tolerability issues 2

Buspirone

• No evidence of efficacy for cannabis use disorder 3

Recommended Treatment Approach

First-Line: Psychosocial Interventions

Cognitive behavioral therapy combined with motivational enhancement therapy is the evidence-based standard 7

• CBT targets cognitive, affective, and environmental risks
• Provides behavioral self-control skills training
• Time-limited, multisession format
• Contingency management may be added for enhanced outcomes 7

Withdrawal Management

For patients experiencing withdrawal symptoms (irritability, insomnia, anxiety, restlessness, appetite changes, abdominal pain):

• Symptoms typically occur within 3 days of cessation and last up to 14 days 6
• Supportive care is primary approach 1
• Consider gabapentin, though evidence is limited 8
• Avoid opioids due to worsening nausea and addiction risk 4

Special Considerations for Comorbidities

Cannabis Hyperemesis Syndrome (CHS)

• Occurs with chronic use (>4 times/week for >1 year) 4
• Acute management: topical capsaicin (0.1%), haloperidol, droperidol, benzodiazepines 4
• Long-term: cannabis cessation is definitive treatment 4
• Tricyclic antidepressants (amitriptyline 75-100 mg at bedtime, starting at 25 mg) for symptom management 4

Psychiatric Comorbidities

• Co-management with psychiatry/psychology recommended 4
• Anxiety and depression are common comorbid conditions 4
• Cannabis may exacerbate psychiatric disorders in vulnerable individuals 6

Clinical Pitfalls to Avoid

1. Do not prescribe pharmacotherapy as monotherapy - always combine with psychosocial interventions if medications are used experimentally 7

2. Recognize cannabis use disorder risk factors:

   • Early age of initiation (especially weekly/daily use) strongly predicts dependence 1, 6
   • 10% of chronic users develop cannabis use disorder 6
   • Medical cannabis card holders have 2x higher incidence of developing disorder (17% vs 9% in 12 weeks) 6

3. Monitor for withdrawal symptoms when patients stop cannabis, even if not seeking treatment for disorder 6

4. Screen for concurrent substance use - nicotine dependence and other illicit drug use are common correlates 9

5. Address driving safety - cannabis users are >2x more likely to be involved in motor vehicle crashes 6

Bottom Line

The evidence remains incomplete for all pharmacotherapies investigated, with most showing low to very low quality evidence. 2 The mainstay of treatment should be evidence-based psychosocial interventions, particularly CBT with or without motivational enhancement therapy and contingency management. Pharmacotherapies should be considered experimental and reserved for research settings or refractory cases where psychosocial interventions have failed. Cannabis cessation counseling remains the definitive long-term management strategy. 4